Abstract:Ethnopharmacological evidenceThe anti-inflammatory effect of Dan-Lou tablets (DLT) have been reported; however, the signaling pathways involved and their role in foam cell formation remains unclear.Aim of the studyThe purpose of this study was to determine the molecular target and mechanism of DLT in the treatment of coronary heart disease (CHD), and investigate the role of DLT in inhibiting foam cell formation and the anti-inflammatory effects of RAW 264.7 macrophages.Materials and methodsThis study explored and elucidated the main active components, therapeutic targets, and pharmacological mechanisms of DLT treatment for CHD using network pharmacology. Secondly, the accuracy of the interaction of key active compounds with key proteins was verified by molecular docking analysis. Eight chemical compositions were determined from the ethanol extract of DLT (EEDL) by high-performance liquid chromatography. Finally, this study used EEDL intervention with oxidized low-density lipoprotein (ox-LDL) to induce RAW264.7 macrophages to verify the results of network pharmacology.ResultsAccording to network pharmacological analysis, 269 common targets of DLT and CHD were obtained from an online database, and 24 key targets were obtained from further analysis. GO enrichment and KEGG analyses were performed, mainly involving the cAMP, cGMP-PKG, MAPK, and NF-κB signaling pathways, and vascular smooth muscle contraction. Molecular docking showed that the active components in DLT docked well with MyD88, NF-κB, and p38 MAPK. The eight compounds from the EEDL have been identified as gallic acid, salvianolic acid, puerarin, daidzein, paeoniflorin, salvianolic acid B, cryptotanshinone, and tanshinone IIA with concentrations of 4.62, 4.76, 23.73, 34.24, 14.59, 21.69, 0.34, and 0.47 μg/mg, respectively. Further in vitro experiments showed that the levels of MyD88 and p-p38 MAPK in RAW 264.7 macrophages induced by ox-LDL increased noticeably. Stimulating the NF-κB signaling pathway increased the release of pro-flammatory factors (TNF-α and IL-1β) and strengthened the inflammatory response (P < 0.05 or P < 0.01), while the levels of MyD88, p38 MAPK, NF-κB, TNF-α, and IL-1β decreased after EEDL treatment (P < 0.05 or P < 0.01).ConclusionThe study demonstrated that the anti-inflammatory activity of the DLT intervention of ox-LDL-induced RAW 264.7 macrophages may involve the MyD88/p38 MAPK/NF-κB signaling pathway.

5-Lipoxygenase activating protein (FLAP) dependent leukotriene biosynthesis inhibition (MK591) attenuates Lipid A endotoxin-induced inflammation.

CCAAT/enhancer-binding Protein Δ is a Critical Mediator of Lipopolysaccharide-Induced Acute Lung Injury.

Inhibition of Myosin Light-Chain Kinase Enhances the Clearance of Lipopolysaccharide-Induced Lung Inflammation Possibly by Accelerating Neutrophil Apoptosis.

Differential impact of 5-lipoxygenase-activating protein antagonists on the biosynthesis of leukotrienes and of specialized pro-resolving mediators

Cathelicidin-WA attenuates LPS-induced inflammation and redox imbalance through activation of AMPK signaling.

Thymol Mitigates Lipopolysaccharide-Induced Endometritis by Regulating the TLR4- and ROS-mediated NF-κB Signaling Pathways

Klf4 Alleviates Lipopolysaccharide-Induced Inflammation by Inducing Expression of MCP-1 Induced Protein 1 to Deubiquitinate TRAF6

Myeloid Cell 5-Lipoxygenase Activating Protein Modulates the Response to Vascular Injury.

Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis

Monophosphoryl lipid A inhibits the cytokine response of endothelial cells challenged with LPS

Regulation of 4-1Bbl-mediated Inflammation at the Late Phase of TLR Response (P1228)

Potential role of a series of lysine-/leucine-rich antimicrobial peptide in inhibiting lipopolysaccharide-induced inflammation.

Lipid A Fraction of Lps Induces A Discrete Mapk Activation in Acute Lung Injury

Lipoxin A yields an electrophilic 15-oxo metabolite that mediates FPR2 receptor-independent anti-inflammatory signaling

Leukadherin-1-Mediated Activation of CD11b Inhibits LPS-Induced Pro-inflammatory Response in Macrophages and Protects Mice Against Endotoxic Shock by Blocking LPS-TLR4 Interaction

Kdo2-Lipid A of Escherichia coli, a defined endotoxin that activates macrophages via TLR-4

Lipoxin A4 activates alveolar epithelial sodium channel gamma via the microRNA-21|[sol]|PTEN|[sol]|AKT pathway in lipopolysaccharide-induced inflammatory lung injury

Lysophosphatidic Acid Receptor 1 Antagonist Ki16425 Blunts Abdominal and Systemic Inflammation in a Mouse Model of Peritoneal Sepsis.

Dan-Lou tablets reduces inflammatory response via suppression of the MyD88/p38 MAPK/NF-κB signaling pathway in RAW 264.7 macrophages induced by ox-LDL

Compound FLZ Inhibits Lipopolysaccharide-Induced Inflammatory Effects Via Down-Regulation of the TAK-IKK and TAK-JNK/p38MAPK Pathways in RAW264.7 Macrophages.

Inhibitor of Tec Kinase, LFM-A13, Decreases Pro-Inflammatory Mediators Production in LPS-stimulated RAW264.7 Macrophages Via NF-κB Pathway